Neurovalens, a global leader in non-invasive neuro-technology, has received medical device clearance from the US Food & Drug Administration (FDA) to treat chronic insomnia with its Modius Sleep device.
Based in Belfast, Neurovalens is a health-tech company that specialises in combining neuroscience and technology to tackle a range of global health challenges.
The company’s medical devices have been designed to deliver non-invasive electrical stimulation to key areas of the brain and nervous system without the need for surgically implanted electrodes.
Modius Sleep is designed to improve insomnia by delivering a small and safe electrical pulse to the head for a period of 30 minutes before bed, during which users can do other activities, such as watching TV or reading.
Dr Jason McKeown, CEO of Neurovalens, said: “Having the Modius Sleep
technology as a certified medical device for the treatment of chronic insomnia is a landmark step for the company as we focus on future growth in the Middle Eastern market. Most other products on the market measure symptoms of insomnia, but Modius Sleep is a non-invasive device that actually treats the underlying issue, improving the lives of our patients.”
Visit the Neurovalens stand in the ABHI UK Pavilion, Hall-2, G30 and learn more about the Modius Sleep technology, try on the headset and speak to the Neurovalens team.
